Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 62   

Articles published

ARNA 2.06 -0.09 (-4.19%)
price chart
South Korea's Ildong Pharma To License Arena Pharma Drug
29, 2012) - U.S.-based Arena Pharmaceuticals, Inc. has licensed its internally discovered thrombosis drug, temanogrel, to Seoul, Korea-based Ildong Pharmaceutical Co.
Vivus Or Arena: Who Has The Edge?
Two of the three major players in the treatment of obesity, VIVUS Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals Inc. (NASDAQ:ARNA) released their financial results and provided an update on recent developments.
Vivus, Arena shares jump on insurance coverage for diet pills
Health insurer Aetna Inc (AET.N) said it would provide coverage for diet pills of Vivus Inc (VVUS.O) and Arena Pharmaceuticals Inc (ARNA.O), sending the obesity drugmakers' shares up. The decision by the third-largest health insurer to provide coverage ...
Vivus, Arena, Orexigen Get a Bounce After Aetna Says It Will Cover Diet Pills
Prescription drug deaths: Two stories
Pete Jackson attended his brother-in-law's funeral along with his daughter, Emily, six years ago. He never dreamed it would be the last day of his daughter's life.
Amgen Therapy Slims Monkeys as Study Seeks Obesity Drug
Nov. 28 (Bloomberg) -- An antibody discovered by Amgen Inc. researchers reduces weight and increases glucose tolerance in monkeys, according to a study, potentially opening up a new approach for treating obesity and diabetes in humans.
How to invest in legalized marijuana
Mark Twain is said to have remarked that a gold rush is a good time to be in the pick and shovel business. Investors may be able to apply that same bit of wisdom to the growing number of U.S.
Local drugmaker expanding by 300 jobs
EAST GREENBUSH - Regeneron Pharmaceuticals is moving ahead with a $70 million expansion at its production facility that will add 300 jobs, boosting employment to 840 people.
Top 10 drug launch disasters
Pharma, for all its deep pockets and big sales forces, often does no better. And the losers are marked down and sold off, or simply shunned by investors.
BioCryst Pharma's (BCRX) BCX4161 Put on Clinical Hold by FDA
During the call, FDA informed the Company that they were applying GMP manufacturing standards to the process of compounding BCX4161 capsules at the clinical site to be used for oral dosing studies.
Xconomist of the Week: Q&A with General Assembly's Brad Hargreaves
The company runs a network of startup schools dedicated to entrepreneurship and education, primarily in the fields of technology, business, and design.